Pipeline

Priority Pipeline Development

Product Candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approval

Program Highlight

DERMATOLOGY

SB206

Molluscum

Target reporting topline results before the end of Q2 2021

Infectious Disease

SB019

Coronavirus

First demonstration of antiviral effect of NO against SARS-CoV-2 in in vitro human airway infection model

Companion Animal

NVN4100 (New Chemical Entity)

Antimicrobial

Seeking potential strategic partner following PoC

Pipeline Expansion Opportunities

Ongoing in-depth review for pipeline prioritization.

Product Candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Program Highlight

Dermatology

SB204

Acne Vulgaris

Two Phase 3s completed, one confirmatory Phase 3 needed; protocol finalized

SB208

Tinea Pedis

Phase 2 trial complete, Phase 1 in nail growth complete

SB414

Atopic Dermatitis

Phase 1b trial completed, Phase 2 protocol finalized

Psoriasis

Phase 1b trial complete, potential to explore lower doses

MEN'S AND WOMEN'S HEALTH

SB207

Genital Warts

End of Phase 2 meeting with FDA complete, Phase 3 protocols designed

WH504

High-Risk HPV

Formulation development ongoing

WH602

High-Risk HPV

Formulation development ongoing

GASTROENTEROLOGY

Undisclosed

Various

Potential Therapeutic Applications of Nitric Oxide:

  • Multifactorial Diseases:

    Acne Vulgaris, Seborrheic dermatitis

  • Viral Infections:

    Warts (HPV), Molluscum contagiosum (pox), Oncoviruses

  • Inflammatory Skin Diseases:

    Psoriasis, Atopic dermatitis, Rosacea

  • Gastrointestinal Diseases:

    Irritable Bowel, Crohn’s

  • Fungal Skin Infections:

    Tinea pedis, onochomychosis

  • Medical Aesthetics:

    Bromhidrosis, Hyperseborrhea, Androgenetic alopecia